4.5 Review

Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies

Journal

Publisher

ELSEVIER
DOI: 10.1016/j.jaip.2016.08.004

Keywords

Primary immunodeficiencies (PIDs); Treatment; Autoimmunity; Cytopenias; Arthritis; Vasculitis; Lupus; Autoimmune enteropathy (AIE); Inflammatory bowel disease (IBD)

Funding

  1. Jeffrey Modell Foundation
  2. Baxalta Biosciences
  3. CSL Behring
  4. NIH
  5. Questcor Pharmaceuticals
  6. Robert Wood Johnson Foundation
  7. [5K08AI103035]

Ask authors/readers for more resources

A broad spectrum of autoimmunity is now well described in patients with primary immunodeficiencies (PIDs). Management of autoimmune disease in the background of PID is particularly challenging given the seemingly discordant goals of immune support and immune suppression. Our growing ability to define the molecular underpinnings of immune dysregulation has facilitated novel targeted therapeutics. This review focuses on mechanism-based treatment strategies for the most common autoimmune and inflammatory complications of PID including autoimmune cytopenias, rheumatologic disease, and gastrointestinal disease. We aim to provide guidance regarding the rational use of these agents in the complex PID patient population. (C) 2016 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma& Immunology. This is an open access article under the CC BY-NC-ND license.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available